SHENYANG, China and VILLA
GUARDIA, Italy, Jan. 25, 2015 /PRNewswire/-- 3SBio Inc., "3SBio",
a leading China-based
biotechnology company focused on researching, developing,
manufacturing and marketing biopharmaceutical products, today
announced that on December 31, 2014,
3SBio acquired the entire share capital of Sirton Pharmaceuticals
SpA ("Sirton") from First Shanghai Limited.
"Expanding 3SBio's footprint in key developed markets is a core
strategic objective for 3SBio," commented Dr. Jing Lou, Chairman and Chief Executive Office of
3SBio Inc. He continued, "With a team of experienced professionals
and a client base of leading pharmaceutical companies, Sirton
provides 3SBio with a solid base to manufacture, develop and market
pharmaceutical products in Europe.
We look forward to working with Sirton's management team and
clients to provide safe, affordable and innovative medicines to
patients across Europe."
Mr. Giorgio Biella, Managing
Director of Sirton, added, "My
colleagues and I look forward to working with the team from 3SBio
as we pursue our common goal of manufacturing high-quality
medicines for international markets." He continued, "3SBio's proven
R&D capabilities, global business development strategies, and
strong financial position will complement Sirton's existing client
relationships and manufacturing experience in Europe."
About Sirton Pharmaceuticals SpA
Sirton Pharmaceuticals SpA ("Sirton") is a pharmaceutical
contract manufacturing company located in Villa Guardia, near
Cuomo, Italy. Sirton produces
injectable pharma products, including pre-filled syringes, liquid
vials, freeze-dried vials and ampoules, and pharmaceutical
development services including lyophilization process development,
analytical method development and validation, stability studies and
manufacturing of clinical study materials. Sirton's customers are
leading international pharmaceutical companies, including Mylan,
Sandoz, Sanofi Avenis France, Crinos and UCB Pharma. Sirton also
develops and produces generic pharmaceutical products including
zoledronic acid, through Ingenerics S.r.l, a joint venture with
Tripharma S.p.A.
For more information visit www.sirton.it.
About 3SBio Inc.
3SBio is a fully integrated, profitable biotechnology company
focused on researching, developing, manufacturing and marketing
biopharmaceutical products primarily in China. Since its founding in 1993, 3SBio's
R&D efforts have resulted in four NDAs for biological
medicines, including TPIAO, the first rhTPO approved worldwide.
Pipeline candidates include Uricase PEG-20, a modified pegylated
recombinant uricase from Candida utilis for the treatment of
refractory gout and tumor lysis syndrome which has completed US
Phase 1 trials; NuPIAO, a long-acting erythropoiesis-stimulating
agent (ESA) for anemia associated with renal failure or
chemotherapy and peri-operative blood cell mobilization which has
received China FDA's approval to initiate clinical trials; SSS07,
an anti-TNF monoclonal antibody for treating rheumatoid arthritis,
psoriasis, and potentially other inflammatory diseases;
Leukotuximab/SSS19, an anti-CD43/JL-1 monoclonal antibody for
treating acute leukemia; and Tanibirumab/SSS23, a anti-VEGFR2
monoclonal antibody for treating solid tumor.
A new state-of-the-art mammalian biological manufacturing
facility in Shenyang is the first
and only rhEPO facility in China
that conforms to both Chinese and European pharmacopeia standards.
Planning is underway to develop monoclonal antibody manufacturing
capabilities.
3SBio is China's leading
specialist in nephrology and oncology supportive care with more
than 600 sales professionals covering over 3,000 hospitals in key
cities supported by a nationwide network of 120 distributors and
logistics providers. EPIAO has been the top selling rhEPO product
in China since 2002 with a market
share over 40%.
Please visit www.3sbio.com for additional information.
3SBio Contact Information
Tan
Bo
|
Jiang Fei,
PhD
|
Tom
Folinsbee
|
Donald
Wyatt
|
Chief Financial
Officer
|
Director, Business
Development
|
Director, Corporate
Development
|
VP, Business
Development & Alliance Management
|
3SBio Inc.
|
3SBio Inc.
|
3SBio Inc.
|
3SBio Inc.
|
B-13, Grand Place 5
Huizhong Road, Chaoyang District, Beijing, China 100101
|
Shenxin Building
801-802, 200 Ninghai Dong Rd, Huangpu District, Shanghai, China
200021
|
Unit 402 Fairmont
House, No.8 Cotton Tree Drive, Admiralty Hong Kong
|
No. 3 A1, Road 10,
Shenyang Economy & Technology Development Zone, Shenyang, China
110027
|
Tel: +86 10 8489
2211
|
Tel: +86 186 4022
0510
|
Tel: +852 8191
6991
|
US Tel: +1 425 516
7491
|
Fax: +86 10 8489
2951
|
Fax: +86 21 6374
4922
|
Fax: +852 3007
9376
|
China Tel: +86 138
1816 5538
|
Email: tanbo@3sbio.com
|
Email: jiangfei@3sbio.com
|
Email: tomfolinsbee@3sbio.com
|
Email: donaldwwyatt@3sbio.com
|
Sirton Pharmaceuticals SpA Contact Information
Giorgio
Biella
Managing
Director
Piazza XX Settembre,
2
22079 Villa
Guardia
Como --
Italy
Tel: +39 031
385343
Fax: +39 031
385329
Email:
gbiella@sirton.it
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/3sbio-acquires-sirton-pharmaceuticals-spa-300025288.html
SOURCE 3SBio Inc.